Combined, these results indicated that high TMEM44‐AS1 expression was related to resistance of GC patients to 5‐FU, and that the evaluation of TMEM44‐AS1 expression contributed to predicting response to 5‐FU therapy among GC cases. Here, TMEM44 is linked to gastric cancer.